Tag: FDA guidance 2025
- 30/Dec/2025
- by William Womack
-
biosimilar approval
FDA biosimilars
biologic alternatives
biosimilar vs generic
FDA guidance 2025
Biosimilar Approval: How the FDA Reviews Biologic Alternatives in 2025
The FDA's 2025 guidance streamlines biosimilar approval by reducing clinical trial requirements, making affordable biologic alternatives faster and cheaper to bring to market. Learn how biosimilars differ from generics and what's changing in U.S. drug access.
Read
